ID: ALA2165451

Max Phase: Preclinical

Molecular Formula: C8H12N2O3

Molecular Weight: 184.19

Molecule Type: Small molecule

Representations

Canonical SMILES:  OCc1cc(OC[C@@H]2CCN2)on1

Standard InChI:  InChI=1S/C8H12N2O3/c11-4-7-3-8(13-10-7)12-5-6-1-2-9-6/h3,6,9,11H,1-2,4-5H2/t6-/m0/s1

Standard InChI Key:  RWITUAISEGLCND-LURJTMIESA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 184.19

Molecular Weight (Monoisotopic): 184.0848

AlogP: -0.09

#Rotatable Bonds: 4

Polar Surface Area: 67.52

Molecular Species: BASE

HBA: 5

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.61

CX Basic pKa: 9.61

CX LogP: -0.83

CX LogD: -3.01

Aromatic Rings: 1

Heavy Atoms: 13

QED Weighted: 0.68

Np Likeness Score: 0.13

References

1. Yu LF, Tückmantel W, Eaton JB, Caldarone B, Fedolak A, Hanania T, Brunner D, Lukas RJ, Kozikowski AP..  (2012)  Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.,  55  (2): [PMID:22148173] [10.1021/jm201301h]

2. Yu LF, Zhang HK, Gunosewoyo H, Kozikowski AP..  (2012)  From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design.,  3  (12): [PMID:23641311] [10.1021/ml3002715]

Source

Source(1):

• Scientific Literature